Child’s Play: Sciele To Boost Pediatric Presence With Alliant Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth $122 million gives Sciele products including Orapred and oral suspension of Allegra.
You may also be interested in...
Sciele’s Antidrooling Liquid Passes Phase III
Orphan drug fleshes out firm’s fast-growing pediatric division.
Sciele’s Antidrooling Liquid Passes Phase III
Orphan drug fleshes out firm’s fast-growing pediatric division.
Sciele/LifeCycle’s “Meltdose” Fenofibrate Clears FDA
Sciele will launch fenofibrate formulation in 40 mg and 120 mg strengths for hyperlipidemia and hypertriglyceridemia by the end of 2007.